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Abstract
Superoxide dismutase (SOD) was chemically modified by covalent linkage of fatty acid chains to the accessible q-amino groups of the
enzyme. This acylation method gave rise to a different enzyme entity (Ac-SOD) as evidenced by different physicochemical properties such as
octanol/water partition coefficient and isoelectric point (pI) as compared to SOD. Ac-SOD was incorporated in conventional and long-
circulating liposomes (LCL) and characterized in terms of incorporation efficiency, protein to lipid ratio (Prot/Lip), enzymatic activity
retention and zeta potential. The observation that Ac-SOD liposomes present enzymatic activity on their external surface indicates that these
formulations can act independent of rate and extent of enzyme release as required in case of SOD liposomes. The decrease of superficial
charge of liposomal formulations containing Ac-SOD, as compared to SOD liposomes, may be related to the negatively charged enzyme
molecules localized on the liposome surface. The comparative characterization of Ac-SOD and SOD liposomal formulations evidenced that
the two enzyme forms differ substantially regarding their intraliposomal location: SOD tends to be localized in the internal aqueous spaces,
whereas Ac-SOD is expected to be localized in the lipid bilayers of the liposomes, partially buried into the outer surface and exposed to the
external medium. These liposomal structures with surface-exposed SOD were designated as Ac-SOD enzymosomes. The properties of these
enzymosomes may influence the therapeutic effect, as the release of the enzyme from extravasated vesicles is no longer a necessary
requirement for achieving dismutating activity within the inflamed target site.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The enzyme Cu,Zn-superoxide dismutase (SOD) was
defined by McCord and Fridovich [1] in 1969 as a natural
defence system that limits the toxic effects of oxygen-
derived free radicals. It catalyses the dismutation of the
toxic superoxide radical anion (O2
 ) to O2 plus H2O2,
disrupting the sequence of biochemical inflammatory pro-
cesses induced by the free radical [2]. Treatment of in-
flammatory pathologies using SOD seems a promising
alternative to conventional anti-inflammatory therapies
based on the use of nonsteroidal anti-inflammatory drugs
avoiding their side effects in particular those involving the
gastrointestinal (GI) tract [3]. However, the clinical appli-
cation of this enzyme is limited by its short half-life time in
the bloodstream and poor penetration into cells. Many
attempts have been made to overcome these limitations
such as covalent attachment of SOD to polyethylene glycol
(PEG) [4,5], dextran [6], albumin [7], modification with
Ficoll [8] and incorporation in liposomes [9–11]. Nakaoka
et al. [4] observed that the coupling of PEG to SOD did not
change the SOD distribution pattern in spleen, lung, heart
and GI tract 24 h post i.v. injection [4]. Turrens et al. [10]
have demonstrated an increased half-life of SOD when
administered in liposome-incorporated form. Unfortunately,
low incorporation efficiencies were obtained due to the
method selected for liposome preparation [10]. Recently,
higher liposomal incorporation efficiencies were achieved
[9,12,13]. The therapeutic activity of these SOD liposomes
may be limited by the rate and degree of release of the
enzyme from liposomes localized at the inflammation site.
The focus of this paper is the preparation of liposomes with
surface-exposed SOD (hereafter referred to as enzymo-
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somes). The presentation of SOD on the liposome surface is
expected to be more beneficial than encapsulation of SOD
in liposomes, as release of enzyme from the liposomes at
the site of inflammation may not be needed to achieve
therapeutic activity. To attain surface localization of SOD
on the enzymosomes, we used the strategy of acylation of
the enzyme by covalent linkage of palmitic acid to q-NH2
groups of SOD (referred to as Ac-SOD). We hypothesized
that the acylation procedure will result in a more hydro-
phobic enzyme with increased affinity for the liposomal
bilayers [14–16]. Besides the goal of exposing SOD on the
external liposome surface, we also aimed for SOD targeting
to inflammation sites. To realize the second aim, we needed
to prepare liposomes with a circulation time long enough to
obtain localization at the inflammation sites. A number of
studies have convincingly demonstrated that so-called long-
circulating liposomes (LCL) tend to localize preferentially
at sites of inflammation after i.v. administration [12,17–19].
The preferential localization appears to be the result of the
inflammatory response provoking a locally increased capil-
lary permeability allowing liposome extravasation [20].
Therefore, LCL have attractive prospects for the targeted
delivery of Ac-SOD.
In the present work, specific attention was paid to a
comparative physicochemical characterization of SOD and
Ac-SOD and to the corresponding liposomal formulations.
SOD and Ac-SOD were incorporated in two types of lip-
osomes: PEG-coated LCL (hereafter referred to as PEG-
liposomes) and non-PEG-liposomes containing stearylamine
(further referred to as SA-liposomes). Both liposomal for-
mulations were characterized with regard to incorporation
efficiency, zeta potential, retention of enzymatic activity and
externally exposed enzyme activity.
2. Materials and methods
2.1. Chemicals
Egg phosphatidylcholine (PC) was obtained from Lipoid
(Ludwigshafen, Germany), distearoylphosphatidylethanol-
amine-poly (ethylene glycol) 2000 (DSPE-PEG) was
obtained from Avanti Polar Lipids (Alabaster, AL, USA).
Cholesterol (Chol), stearylamine (SA), dimiristoylphospha-
tidylcholine (DMPC) and bovine erythrocyte Cu,Zn-SOD
was purchased from Sigma (St. Louis, MO, USA). Sepha-
dex G-200 was purchased from Pharmacia Biotech,
Uppsala, Sweden. All other chemicals were of analytical
grade.
2.2. Chemical modification of SOD
The Ac-SOD was prepared as previously described
[21,22]. Briefly, palmitoyl chloride was added to a 50-mM
carbonate buffer (pH 9.4) containing 1% sodium cholate.
The mixture was sonicated for 90 s and immediately added
to the enzyme and incubated with gentle stirring at room
temperature for 2 h. To promote the separation of the excess
of the palmitoyl chloride, hydrolysed to palmitic acid and
remaining in suspension by the presence of the sodium
cholate micelles, the preparation was diluted with equal
volume of cold water and placed in a refrigerator to achieve
a temperature of 5 jC. The palmitic acid was then removed
by centrifugation at 20,000 g for 30 min at 6 jC (Sigma
202 MK, Laboratory centrifuge, Osterode, Germany). The
remaining compounds were removed by dialysis against
water for 72 h. A final centrifugation at 20,000 g for 1 h at
6 jC (Sigma 202 MK, Laboratory centrifuge) was carried
out and the supernatant containing Ac-SOD was lyophilised
either for incorporation in liposomes or for physicochemical
characterization. Native enzyme was used as a reference in
all modification steps.
The modification degree of Ac-SOD was determined by
a fluorimetric assay. Briefly, unblocked q-NH2 groups were
bound to fluorescamine according to the method of Bo¨hlen
et al. [23]. The fluorescence intensity was measured in all
samples (kex = 390 nm; kem = 475 nm) in a fluorescence
spectrophotometer F3000, Hitachi, Japan. The modification
degree, representing the percentage of accessible q-NH2
groups covalently linked to hydrophobic palmitoyl chains,
was defined as:
ð1 ðemission of 20 Ag modified enzymeÞ
=ðemission of 20 Ag native enzymeÞÞ100:
2.3. Liposome preparation and characterization
2.3.1. Incorporation methods
Multilamellar liposomes were prepared by the simple
dehydration– rehydration method (sDRV) as previously
described [15]. Briefly, the selected lipid mixtures were
dried under a nitrogen stream. The obtained homogeneous
film was dispersed in water (16 or 32 Amol/ml) to form
empty multilamellar vesicles. The lipid compositions were
PC, Chol and SA at a molar ratio of 7:2:1 for conventional
liposomes (SA-liposomes), PC, Chol and DSPE-PEG at a
molar ratio of 1.85:1:0.15 for pegylated liposomes (PEG-
liposomes) and DMPC for thermotropic behaviour studies.
To prepare Ac-SOD liposomes, 1 ml of empty liposomes
was added to the lyophilised protein, frozen and lyophilised
overnight. The lyophilised powder was rehydrated in the
presence of 0.1 ml of 280 mM mannitol in 10 mM citrate
buffer (pH 5.6). The hydration step lasted 30 min, and after
that, 145 mM NaCl in 10 mM citrate buffer (pH 5.6) was
added to adjust up to 1 ml. The liposomes were sequentially
extruded through polycarbonate membranes of different
porosities. Gel filtration was the technique selected for
removing the non-incorporated Ac-SOD from Ac-SOD lip-
osome preparations as it showed higher lipid recovery (81%
vs. 69%) and was easier than the discontinuous sucrose
gradient centrifugation.
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SOD liposomes were prepared according to Corvo et al.
[9]. Briefly, liposomes were prepared as described for Ac-
SOD liposomes with the following modifications. The film
was dispersed in an aqueous solution of SOD, the non-
incorporated SOD was separated from liposome suspension,
after extrusion steps, by ultracentrifugation at 250,000 g
for 3 h at 10 jC (LM-80 ultracentrifuge, Beckman).
Two different liposome types were used in this study:
PEG-liposomes (composed of PC/Chol/DSPE-PEG) and
SA-liposomes (composed of PC/Chol/SA). To study the
effect of particle size on the IE, SA- and PEG-liposomes
were extruded until reaching a mean diameter of about 0.2
or 0.1 Am. According to size (0.2 or 0.1 Am), SA-liposomes
are designated as SA (0.2) or SA (0.1) and PEG-liposomes
as PEG (0.2) or PEG (0.1).
2.3.2. Incorporation parameters
Liposomes were characterized by lipid composition, size
and by the following incorporation parameters: incorpora-
tion efficiency, protein recovery, protein-to-lipid ratio, enzy-
matic activity and zeta potential.
Abbreviations and equations used to determine incorpo-
ration parameters: Prot—protein; Lip—lipid; (Prot/Lip)i—
initial (Prot/Lip); (Prot/Lip)f—final (Prot/Lip); initial (Prot/
Lip)—initial Prot to Lip ratio (Ag/Amol of Lip); final (Prot/
Lip)—final Prot to Lip ratio (Ag/Amol of Lip); incorporation
efficiency (%)=({final (Prot/Lip)}/{initial (Prot/Lip)})
100—(IE).
The protein was determined using the method described
by Lowry et al. [24] after disruption of the liposomes with
Triton X-100 and sodium dodecyl sulfate (SDS) [25]. Lipid
determinations were performed using the method described
by Rouser et al. [26].
The enzymatic activity of Ac-SOD and SOD formula-
tions was determined according to Misra and Fridovich
[27] and Sun and Zigman [28]. The ability of the enzyme
to decrease the rate of autoxidation of epinephrine to
adrenochrome was measured at pH 10.2 (Abs = 480 nm)
[27,28]. For total enzymatic activity determination of SOD
or Ac-SOD incorporated in liposomes, appropriated dilu-
tions must be done to prepare a final protein concentration
of 6 Ag/ml with a maximum of 0.3% Triton X-100. For the
determination of the enzymatic activity exposed to the
external surface (Exp. Act.), dilutions of SOD or Ac-
SOD liposomes with 0.145 M NaCl/10 mM citrate buffer
(pH 5.6) must be done to prepare a final protein concen-
tration of 12 Ag/ml. A curve of the inhibition (%) of the
autoxidation of epinephrine as a function of amount of
SOD or Ac-SOD is plotted. The amount (Ag) of SOD or
Ac-SOD required to inhibit 50% of the epinephrine autox-
idation is calculated. The retention of enzymatic activity is
calculated as follows:
The total retention of enzymatic activity (Ret. Act.) of
Ac-SOD in the studied formulations was defined as the
ratio, in percentage, of the enzymatic activity quantified on
the final liposomes and on the initial rehydrated liposomes,
after disruption of liposomes in both samples with Triton X-
100 at 5%. The enzymatic activity exposed to the external
surface was quantified in intact liposomes (without disrup-
tion with Triton X-100). This parameter, exposed activity
(Exp. Act.) corresponds to the ratio, in percentage, of the
enzymatic activity of Ac-SOD exposed to the external
surface in relation to the total enzymatic activity of the final
liposomes when disrupted with detergent.
Liposome mean diameter (F) was determined by
dynamic light scattering in a ZetaSizer 1000 HSA (Malvern,
UK). As a measure of particle size distribution of the
dispersion, the system reports the polydispersity index (PI)
ranging from 0.0 for an entirely monodisperse sample up to
1.0 for a polydisperse suspension.
Zeta potential was calculated by using Smoluchowsk’s
equation in a ZetaSizer 2000 (Malvern). The scattering
angle was 12j and the electric field intensity ranged from
18.5 to 19.6 V/cm.
Statistical analysis was performed by the unpaired two-
tailed Student’s t test, and differences with P values < 0.05
were considered significant.
2.4. Thermotropic behaviour of phospholipid membranes
Phase-transition temperature of liposomal formulations
was determined as previously described [29] by light
scattering in a fluorescence spectrophotometer (F3000,
Hitachi), with an excitation and emission wavelength set
at 450 nm, connected to a thermostatically controlled bath.
Liposomes made with DMPC either unloaded or with Ac-
SOD incorporated were prepared. Aliquots of the liposomal
formulations under study were added to a fluorescence cell
and light scattering recorded. The temperature of the sam-
ples was changed by increments of 0.5–1 jC in the range
between 19 and 30 jC.
3. Results
3.1. Physicochemical characterization: Ac-SOD vs. SOD
A comparative physicochemical characterization of Ac-
SOD and SOD is presented in Table 1. The acylated enzyme
presents a modification degree of 30%, meaning that 30% of
the accessible q-NH2 are covalently linked to hydrophobic
palmitoyl chains. The enzymatic activity of Ac-SOD was
only reduced 10% as compared to SOD. The octanol/water
partition coefficient was 3.13 for Ac-SOD and 0.15 for
SOD. The 20-fold increase in this value evidences the
hydrophobic character of the acylated enzyme.
A slight decrease on the pI was observed upon acylation.
The zeta potential of Ac-SOD had a higher negative value as
½ððAg SOD or Ac SOD ðcontrol solutionÞÞ
=ðAg SOD or Ac SOD ðfinal preparationÞÞ 100
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compared to SOD. The decrease either of the pI or of the
zeta potential may be related to blockage of some q-NH2
groups of SOD by palmitic chains.
3.2. Incorporation of Ac-SOD in liposomes
3.2.1. Effect of lipid concentration and particle size on
incorporation parameters
For liposome preparation, it is desirable to obtain high
protein loading efficiencies. The effect of the lipid concen-
tration on the drug loading of the final liposomal formula-
tions was studied. The increase of the initial lipid
concentration for SA-liposomes, from 16 to 32 Amol/ml,
resulted in a 2-fold increase of the IE (from 31% to 63%)
and in an increase of the protein recovery from 25% to 38%.
Therefore, the initial lipid concentration used for subsequent
studies was set at 32 Amol/ml.
Fig. 1 shows that the Ac-SOD IE was dependent from
lipid composition rather than on the particle size. A higher
IE and final (Prot/Lip) were obtained for SA-liposomes
(58F 4%–63F 7% and 8F 1 Ag/Amol, respectively) as
compared to PEG-liposomes (43F 5% and 6F 1 Ag/Amol,
respectively). The preservation of enzymatic activity of Ac-
SOD liposomes is an important parameter to evaluate the
effect of suitability of the incorporation method and to
characterize the obtained formulations.
The total retention of enzymatic activity (Ret. Act.) of
Ac-SOD ranged from 82% to 94% for all liposomal for-
mulations tested (Fig. 1), attesting that the incorporation
method could preserve the activity of the enzyme.
3.3. Effect of protein-to-lipid ratio on properties of SA-
liposomes containing Ac-SOD
Table 2 shows the effect of the initial (Prot/Lip) on the
IE, final (Prot/Lip), enzymatic activity exposed on the
liposome surface and zeta potential of SA-liposomes con-
taining Ac-SOD. The effect of the initial (Prot/Lip) on the IE
of Ac-SOD was roughly as follows: a 4- to 5-fold increase
of the initial (Prot/Lip) resulted in a 2- to 3-fold increase of
the final (Prot/Lip) and a 2-fold decrease of the IE. Appa-
rently, saturation was not achieved over the initial (Prot/Lip)
range studied. In previous work, concerning the incorpo-
ration of SOD in SA-liposomes, similar results were
obtained [9,12].
At an initial (Prot/Lip) of 13 Ag/Amol, 30% of the total
liposome-bound enzymatic activity is exposed on the lip-
osome exterior, evidencing that surface-bound enzyme mol-
ecules are able to convert substrate molecules in the
surrounding medium. A 4- to 5-fold increase of the initial
Table 1
Physicochemical characterization of SOD and Ac-SOD
Enzyme Ac-SOD SOD
Modification degree (%) 30a 0a
Activity retention (%) 90a 100a
Partition coefficientb 3.13a 0.15a
Isoelectric point (pI) 4.83a 4.96a
Molecular weight (kDa) 36a 36a
Zeta potential (mV)  16.7c  5.7c
a Data previously published [22].
b Octanol/water partition coefficient.
c In citrate buffer, pH 5.6, 28 mosM.
Fig. 1. Incorporation parameters of Ac-SOD in SA- and PEG-liposomes.
Influence of the lipid composition and mean diameter of liposomes on: final
(Prot/Lip)—white columns; total enzymatic activity retention (Ret. Act.
%)—grey columns; IE (%)—black columns. SA-0.1 and SA-0.2—
conventional liposomes with mean diameters of 0.1 or 0.2 Am, respectively.
PEG-0.1 and PEG-0.2—LCL with mean diameters of 0.1 or 0.2 Am,
respectively. The initial lipid concentration was 32 Amol/ml and the initial
protein concentration was 500 Ag/ml. The results represent meansF S.D. of
at least three preparations.
Table 2
Effect of initial (Prot/Lip) on liposome properties of SA-liposomes
incorporating Ac-SOD
(Prot/Lip)i
(Ag/Amol)
(Prot/Lip)f
(Ag/Amol)
IE (%) Enzymatic
activity (%)
Exposed
enzymatic
activity (%)
Zeta
potential
(mV)
13F 2 8F 1 60F 3 93F 1 30F 2 31F1
36F 2 15F 1 43F 2 92F 2 37F 3 28F 1
57F 5 20F 1 36F 3 94F 2 49F 3 26F 1
Initial protein concentration—500–2500 Ag/ml.
Initial lipid concentration—32 Amol/ml.
SA-liposomes incorporating Ac-SOD with a mean size of 0.2 Am.
Liposomes were rehydrated with citrate buffer, pH 5.6, 280 mosM.
Values are meansF S.D. of at least three independent preparations.
Table 3
Ac-SOD and SOD liposomal formulations: physicochemical character-
ization
Liposomes
(enzyme)
(Prot/Lip)i
(Ag/Amol)
(Prot/Lip)f
(Ag/Amol)
IE (%) F (Am) (PI)
PEG-Ac-SOD 24F 4 13F 2 54F 4 0.10F 0.02 ( < 0.12)
PEG-SOD 100F 5 18F 1 18F 3 0.10F 0.01 ( < 0.12)
SA-Ac-SOD 20F 3 12F 2 60F 5 0.12F 0.02 ( < 0.15)
SA-SOD 44F 2 17F 3 39F 2 0.11F 0.02 ( < 0.12)
PEG-Ac-SOD—LCL incorporating chemically modified SOD.
SA-Ac-SOD—conventional liposomes incorporating chemically modified
SOD.
PEG-SOD—LCL incorporating native SOD.
SA-SOD—conventional liposomes incorporating native SOD.
Values are meansF S.D. of at least three independent preparations.
M.M. Gaspar et al. / Biochimica et Biophysica Acta 1609 (2003) 211–217214
(Prot/Lip) yielded a 1.5-fold increase of the Exp. Act. This
success in designing enzymosomes with 30–50% of the
enzymatic activity exposed on the surface is critical for the
evaluation of the basic hypothesis behind the present work:
surface-located enzyme is to be preferred over release of
enzyme for achieving therapeutic activity.
Liposome surface charge is a crucial determinant factor
of the biological behaviour of liposome particles. The
inclusion of SA in the liposomes confers a positive zeta
potential. The incorporation of Ac-SOD, enzyme with a
negative zeta potential ( 16.7 mV) affects the zeta poten-
tial of SA-liposomes incorporating this enzyme (Table 2).
An increase of final Prot/Lip corresponds to a decrease of
the Ac-SOD liposome zeta potential from 31 to 26 mV.
3.4. Effect of Ac-SOD on thermotropic behaviour of
phospholipid bilayers
To determine to what extent the Ac-SOD interacts with
the lipid bilayers, we measured the effect of Ac-SOD on the
thermotropic behaviour of DMPC bilayers. We found that
the phase-transition pattern of such liposomes changed from
a sharp peak at 23.5 jC in control vesicles to a wide peak
ranging from 22 to 25 jC, with the same overall heat
content, after incorporation of the Ac-SOD.
3.5. Comparison of Ac-SOD enzymosomes and SOD
liposomes
3.5.1. Physicochemical characterization, enzymatic activity
and zeta potential
The IE of Ac-SOD either in SA-liposomes or PEG-
liposomes was substantially higher in comparison with
SOD (Table 3). For enzymosomes containing Ac-SOD,
the IE was 1.5-fold higher in SA-liposomes and 3-fold
higher in PEG-liposomes compared to the corresponding
values for liposomes containing SOD. From a drug loading
capacity point of view, this difference is translated to the
need for using two to four times more SOD than Ac-SOD to
reach the same final (Prot/Lip): 12–18 Ag of protein to
micromoles of lipid.
The enzymatic activity of Ac-SOD enzymosomes was
compared with SOD liposomes (Fig. 2). The total retention
of enzymatic activity associated with the liposome disper-
sions ranged from 82% to 94%, irrespective of the form of
the enzyme, liposome type or size. This confirms that the
experimental conditions used in this work did not affect the
enzymatic activity. The Exp. Act. of Ac-SOD enzymosomes
is 3- to 4-fold higher than that of SOD liposomes, which is
Fig. 2. Enzymatic activity retention of Ac-SOD and SOD incorporated in
SA- and PEG-liposomes. Influence of the mean diameter (0.1 and 0.2 Am)
on the total retention of enzymatic activity (Ret. Act.), and on the exposed
enzymatic activity (Exp. Act.) to the liposome surface: SA-Ac-SOD-0.1
(W) and SA-Ac-SOD-0.2 ( ): SA-liposomes with a mean diameter of 0.1
or 0.2 Am incorporating Ac-SOD. SA-SOD-0.2—SA-liposomes (n) with a
mean diameter of 0.2 Am incorporating native SOD. PEG-Ac-SOD-0.1 (5)
and PEG-Ac-SOD-0.2 ( ): PEG-liposomes with a mean diameter of 0.1 or
0.2 Am incorporating Ac-SOD. The initial lipid concentration was 32 Amol/
ml and the initial protein concentration was 500 Ag/ml. The results
represent meansF S.D. of at least three preparations.
Table 4
Effect of nature of the incorporated enzyme (Ac-SOD or SOD) on liposomes zeta potential
Liposome SA
(Unloaded lip.)
SA-SOD SA-Ac-SOD PEG
(Unloaded lip.)
PEG-SOD PEG-Ac-SOD
Zeta
potential
(mV)
20F 2 22F 1 14F 1  3F 1  4F 1  5F 1
F (Am)
(PI)
0.16F 0.01
( < 0.15)
0.16F 0.02
( < 0.17)
0.19F 0.02
( < 0.2)
0.17F 0.01
( < 0.10)
0.17F 0.01
( < 0.10)
0.16F 0.01
( < 0.12)
Initial protein concentration—500–700 Ag/ml.
Initial lipid concentration—32 Amol/ml.
PEG-Ac-SOD—LCL incorporating chemically modified SOD.
SA-Ac-SOD—conventional liposomes incorporating chemically modified SOD.
PEG-SOD—LCL incorporating native SOD.
SA-SOD—conventional liposomes incorporating native SOD.
Unloaded lip.—liposomes devoid of protein.
Liposomes were rehydrated with citrate buffer, pH 5.6, 28 mosM.
Liposomes were sequentially extruded through polycarbonate membranes of different porosities. The last filter had a porosity of 0.1 Am.
Values are meansF S.D. of at least three independent preparations.
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less than 10%. For vesicles containing Ac-SOD, the Exp.
Act. was similar for both SA-enzymosomes and for PEG-
enzymosomes with the same size. Larger liposomes with a
mean diameter of 0.2 Am, had a lower Exp. Act. than 0.1-
Am liposomes: 29% and 35% for SA-enzymosomes and for
PEG-enzymosomes, respectively.
Table 4 compares the zeta potential of SA and PEG
unloaded liposomes with the corresponding liposomes
incorporating either Ac-SOD or SOD. SA-liposomes con-
taining SOD showed a similar zeta potential as compared to
unloaded SA-liposomes (20–22 mV). In contrast, the incor-
poration of negatively charged Ac-SOD molecules in SA-
liposomes decreased the positive zeta potential by 8 mV. For
PEG-liposomes, no statistically significant differences
(P>0.05) in zeta potential values were observed between
unloaded and Ac-SOD loaded liposomes.
4. Discussion
The chemical modification of SOD gave rise to a differ-
ent enzyme entity [22] and so new methodologies to
incorporate and characterize Ac-SOD were developed in
this work. To reveal whether the use of Ac-SOD may offer
advantages over SOD, galenic and pharmaceutical proper-
ties of respective liposomal forms were compared. The
higher incorporation parameters obtained for Ac-SOD lip-
osome formulations evidence the higher affinity of Ac-SOD
for the hydrophobic region of the liposomal bilayers as
compared to SOD. The higher IE of Ac-SOD in SA-lip-
osomes compared to PEG-liposomes observed for lower
initial (Prot/Lip) ratios (Fig. 1) may be due to the competi-
tion of Ac-SOD with Chol for the insertion in the liposomal
bilayers. This competition is dependent on the molar
amount of the sterol: 20 mol% in SA-liposomes and 33
mol% in PEG-liposomes and on the ratio of Protein to Chol
being this effect negligible when the initial (Prot/Lip)
increases (Table 3). This finding is in agreement with
literature [30,31] where the competition of hydrophobic
drugs with Chol is described. Another possible explanation
could be the different electrostatic interactions occurring
between the negatively charged Ac-SOD and the bilayers.
The positively charged SA-liposomes can favour these
interactions while the presence of the PEG at LCL surface
may reduce the protein–lipid charge–charge interactions
[32]. While in vitro toxicity against L1210 cells was
observed, it was also shown that liposomes containing SA
are less toxic than free SA [33]. Other experiments using
SA-liposomes incorporating L-asparaginase showed less
toxicity than free enzyme against Chinese hamster ovarian
cells [34]. The observation that Ac-SOD enzymosomes
present considerable enzymatic activity on their surface
indicates that they can act independently of the rate and
extent of enzyme release, as required in the case of SOD
liposomes and so they can have a different mechanism and
therapeutic action. The proportion of exposed Ac-SOD is
somewhat larger for the smaller liposomes than for the
larger. This effect may be explained by the larger exposed
surface area of the smaller liposomes, which have a lower
degree of lamellarity [35–37].
The influence of the negative charge of Ac-SOD mole-
cules on the zeta potential of Ac-SOD liposomes was
observed for SA-liposomes but not for PEG-liposomes.
This is in according to Zeisig et al. [38] as the presence of
PEG causes a masking effect on the surface charge of
liposomes.
The widening of the thermotropic phase-transition peak
by incorporation of Ac-SOD into DMPC vesicles indicates a
decrease in cooperativity of the phase transition. This would
be compatible with a perturbation of the acyl chain packing
in the bilayers and thus with a hydrophobic interaction of
the palmitoyl chains of the Ac-SOD with DMPC acyl
chains. Native SOD encapsulated in DPPC liposomes was
shown not to have such an effect [39].
Based on the above results, we propose that the two
enzyme forms differ substantially regarding their intralipo-
somal location: SOD tends to be localized in the internal
aqueous space with the additional possibility of electrostatic
interaction with the cationic bilayers of SA-liposomes. The
hydrophobic Ac-SOD is expected to interact with the acyl
chain region of the bilayers, although electrostatic interac-
tions between the protein and the interface of the bilayers
are also likely to occur in the case of positively charged SA-
liposomes.
The present results allow us to conclude that it is possible
to design enzymosomes that display significant enzymatic
activity on their surface via the use of acylated enzyme.
Another important finding is that the surface-exposed
enzyme is still able to convert substrate despite the presence
of PEG chains on the surface of the PEG-enzymosomes.
The PEG coating utilized was apparently not a barrier for
the substrate to reach the exposed enzyme molecules. This
point is crucial for the intended therapeutic application of
PEG-enzymosomes containing Ac-SOD, as release of
enzyme from extravasated liposomes is no longer a prereq-
uisite for the dismutating activity within the inflamed target
site. Ac-SOD enzymosomes made with PEG are circulating
microreservoirs joining together the advantages of express-
ing activity before disruption and a sustained release pattern
of the enzyme.
We envisage that Ac-SOD enzymosomes can be ther-
apeutically used in the following ways: (1) for passive
targeting to inflammation sites with a subsequent rapid
and intense effect in rheumatoid arthritis, and (2) as long-
circulating enzymatically active particles for the treatment
of other diseases such as ischemia/reperfusion pathologies.
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